Elotuzumab
Elotuzumab is a humanized monoclonal antibody used in relapsed multiple myeloma. The package insert denotes its mechanism as a SLAMF7-directed immunostimulatory antibody.In May 2014, it was granted "Breakthrough Therapy" designation by the FDA. On November 30, 2015, FDA approved elotuzumab as a treatment for patients with multiple myeloma who have received one to three prior medications. Elotuzumab was labeled for use with lenalidomide and dexamethasone. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen. In May 2016 the EC/EU gave a similar approval.
